Management Team
Our management team has a proven track record of successfully developing and commercializing pharmaceuticals while maintaining a distinct focus on efficient, entrepreneurial business processes.

Prior to HemaFlow, Martino was President and CEO of Ambit Biosciences, a San Diego-based company developing a drug to treat Acute Myeloid Leukemia, from November 2011 to November 2014. Under his leadership, Ambit initiated a large, multi-national Phase 3 study; secured $25 million in private financing; completed a $90 million IPO; and ultimately sold the company to a large, Japanese pharmaceutical company for $450 million in cash plus future milestone payments.
Mr. Martino previously served as CEO, President, and Director of Arzeda, a synthetic biology company, and Sonus Pharmaceuticals, an oncology drug development company. He was also a founding Director at Excision Biotherapeutic,
Martino’s career began with Mallinckrodt, where he held over 20 discreet assignments in planning, business development, marketing, and general management over his 17-year tenure.
Martino has a BBA from Roanoke College, where he served as a Trustee from 2016 to 2020, and an MBA from Virginia Tech.